Sensorion SA (EPA:ALSEN)

Market Cap	123.50M
Revenue (ttm)	6.65M
Net Income (ttm)	-25.97M
Shares Out	300.49M
EPS (ttm)	-0.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	101,599
Average Volume	58,653
Open	0.4420
Previous Close	0.4310
Day's Range	0.4110 - 0.4420
52-Week Range	0.4110 - 0.9700
Beta	1.38
RSI	22.40
Earnings Date	Mar 17, 2025

About Sensorion

Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. Its pipeline includes various products in the development stage for restoring, treating, and preventing inner ear related disorders. The company’s product portfolio includes SENS-401 SSNHL, which has completed Phase 2 clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2 clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, which is in Phase 2 cli...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 57
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALSEN

Financial Performance

In 2024, Sensorion's revenue was 6.65 million, an increase of 16.76% compared to the previous year's 5.70 million. Losses were -25.97 million, 17.7% more than in 2023.